EGFR and neoplasm: Furthermore, we divided the EGFR-mutant NSCLC into a low ΔCT value and a high ΔCT value to explore whether the ΔCT value of the tumor sample could be a predictor for the efficacy of EGFR-TKIs in EGFR-mutant NSCLC patients.